The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BELLUS Health Inc. (NASDAQ: BLU) alleging that the Company violated federal securities laws.
Class Period: September 5, 2019 and July 5, 2020
Lead Plaintiff Deadline: May 17, 2021
Learn more about your recoverable losses in BLU:
The filed complaint alleges that BELLUS Health Inc. made materially false and/or misleading statements and/or failed to disclose that: while BLU-5937's "high selectivity" contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company's Phase 2 trial.
Shareholders have until May 17, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
For additional information about the BLU lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/77708